Friday, January 24, 2025
8.30-8.40 Opening
Heinz Ludwig and Jesús F. San Miguel
MYELOMA BIOLOGY AND RISK STRATIFICATION
Moderator: Heinz Ludwig
8.40-9.00 Evolution patterns from MGUS to multiple myeloma
Niccolò Bolli
9.00-9.20 The role of the bone marrow microenvironment in the evolution and course of myeloma
Martin Kortüm
9.20-9.40 New risk classification of multiple myeloma
Herve Avet Loiseau
9.40-10.10 Discussion around important questions
• Do genomic patterns predict risk of progression of MGUS/SMM
• What can be done to strengthen the immune environment
• Hurdles for the implementation of the new risk classification
• Non-genomic risk classifiers
10.10-10.30 BREAK
NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT
Moderator: Jesús San Miguel
10.30-10.50 Diagnostic workup of monoclonal gammopathies
Kwee Yong
10.50-11.10 New development in imaging for diagnosis and prognostication
Elena Zamagni
11.10-11.30 Response assessment – technical and clinical considerations
Bruno Paiva
11.30-12.00 Discussion around important questions
• When is a bone marrow biopsy required in MGUS?
• Circulating plasma cells for disease and response assessment
• Optimizing imaging technologies – MRI and PET/CT
• Comparison of different mass spectrometry techniques (MALDI-TOF, clonotypic peptide detection approach)
• Is MRD assessment in MGUS-like MM useful?
WORKSHOPS
12.00-12.30 Prevention and treatment of bone disease
Evangelos Terpos
12.00-12.30 Prevention and Management of infections in multiple myeloma
Heinz Ludwig
12.00-12.30 Management of extramedullary myeloma, solitary plasmocytoma and plasma cell leukemia
Meral Beksac
12.30- 13.30 LUNCH
MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE
Moderator: Heinz Ludwig
13.30-13.50 High risk smoldering myeloma: to treat or not to treat
Mario Boccadoro
13.50-14.10 Quadruplets and beyond for first line therapy of transplant eligible patients
Philippe Moreau
14.10-14.30 Game changing results from recent EMN trials
Pieter Sonneveld
14.30-14.50 Maintenance treatment with lenalidomide and beyond
Francesca Gay
14.50-15.20 Discussion around important questions
• Can the prediction of early progression in SMM be further improved?
• Can upfront ASCT be deferred or abandoned in good risk patients in the era of novel quadruplets?
• What is the optimal number of induction and consolidation cycles?
• MRD guide therapy ready for prime time?
• New concepts for maintenance therapy
15.20-15.40 BREAK
MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS
Moderator: Jesús San Miguel
15.40-16.00 The impact of frailty and comorbidities on treatment selection
Charlotte Pawlyn
16.00-16.20 Treatment of TNE patients, today and tomorrow
Thierry Facon
16.20-16.50 Discussion of important questions
• Treatment of very elderly patients
• How to distinguish between myeloma and patients related comorbidities?
• Initiation of therapy at biochemical progression?
• Treatment duration
• Impact of patient risk factors on treatment selection
16.50- 17.00 BREAK
17.00-17.30 WORKSHOPS (repeated)
KEYNOTE LECTURE
17.30-18.00 Important milestones in the management of multiple myeloma and strategies for further advancements
Jesús San Miguel
Saturday, January 25, 2025
THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE
Moderator: Jesús San Miguel
8.30-8.50 How to select treatment after relapse
Maria-Victoria Mateos
8.50-9.10 My approach to patients with high-risk disease
Martin Kaiser
9.10-9.30 Indications for less frequently used drugs including Blenrep, Selinexor, Melflufen, Venetoclax and new IMiDs
Evangelos Terpos
9.30-10.00 Discussion of important questions
• Limitations of the definition of refractoriness
• Management of early relapse
• Lenalidomide refractory patients
• CD38 retreatment
• Optimizing therapy in high-risk RRMM patients
10.00-10.20 BREAK
HOT TOPICS IN MYELOMA
Moderator: Heinz Ludwig
10.20-10.40 How to optimize use of bispecific antibodies
Niels van de Donk
10.40-11.00 Cellular therapies in MM, present options and outlook
Hermann Einsele
11.00-11.30 Discussion of important questions
• Is there a preferred target for BsAbs and CAR-T cells?
• Pros and cons for BsAbs or CAR-T cells
• Impact of CAR-T cell persistence on outcome
• Prevention of toxicities of BsAbs and CAR-T cells
AMYLOIDOSIS AND WADENSTRÖM’S DISEASE
Moderator: Heinz Ludwig
11.30-11.50 Treatment approaches in Waldenström’s disease
Meletios A. Dimopoulos
11.50-12.10 Recent developments Amyloidosis research and therapy
Giovanni Palladini
12.10-12.40 Discussion of important questions
• Is cure a realistic goal in amyloidosis?
• Cellular therapies in amyloidosis
• Treatment of patients failing to first-line treatment with BTK inhibitors and CD20+ based therapies
• Is there a role for anti-BCMA treatments in Waldenström’s disease as 2/3 express BCMA on their tumor clones?
12.40-12.50 Closure of the meeting
Heinz Ludwig